World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
55
Citations
11094
World Ranking
3815
National Ranking
111

Overview

Josep Mallolas is affiliated with the University of Barcelona in Spain. Their research primarily focuses on infectious diseases, with a strong emphasis on HIV/AIDS and related complications.

The researcher's main fields of study include:

  • Medicine

The subfields of study associated with their work are:

  • Infectious Diseases
  • Epidemiology
  • Virology
  • Emergency Medicine
  • Hepatology

Mallolas has contributed extensively to topics such as:

  • HIV/AIDS Research and Interventions
  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment
  • HIV-related health complications and treatments
  • HIV, Drug Use, Sexual Risk
  • COVID-19 Clinical Research Studies
  • Hepatitis C virus research

The researcher's recent papers include:

  • COVID-19 in patients with HIV: clinical case series (2020), published in The Lancet HIV
  • Overview of SARS-CoV-2 infection in adults living with HIV (2021), published in The Lancet HIV
  • Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study (2020), published in AIDS
  • Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study (2021), published in The Lancet HIV
  • Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre (2021), published in Journal of Antimicrobial Chemotherapy

The frequent co-authors collaborating with Josep Mallolas include:

  • Juan Ambrosioni
  • Lorena de la Mora
  • Ana González-Cordón
  • Elisa de Lazzari
  • José Luís Blanco

Mallolas' work has been published predominantly in the following journals:

  • Journal of Antimicrobial Chemotherapy
  • Infectious Diseases and Therapy
  • The Lancet HIV
  • Enfermedades Infecciosas y Microbiología Clínica
  • Enfermedades infecciosas y microbiologia clinica (English ed )

Best Publications

  • Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

    Esteban Martínez;Amanda Mocroft;Miguel A García-Viejo;José B Pérez-Cuevas

  • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

    Montserrat Laguno;Javier Murillas;José Luis Blanco;Esteban Martinez

  • Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.

    Esteban Martinez;José L. Blanco;Juan A. Arnaiz;José B. Perez-Cuevas

  • COVID-19 in patients with HIV: clinical case series.

    Jose L Blanco;Juan Ambrosioni;Felipe Garcia;Esteban Martínez

  • Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

    Juan Berenguer;Julio Álvarez‐Pellicer;Pilar Miralles Martín;José López‐Aldeguer

  • Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): A non-randomised, open-label trial

    Jürgen K. Rockstroh;Mark Nelson;Christine Katlama;Jay Lalezari

  • Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

    Mark Sulkowski;Christophe Hezode;Jan Gerstoft;John M Vierling

  • Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study.

    Luz Martín-Carbonero;Yves Benhamou;Massimo Puoti;Juan Berenguer

  • A prospective study of the risk of tuberculosis among HIV-infected patients.

    A Guelar;J M Gatell;J Verdejo;D Podzamczer

  • Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count

    Felipe García;Elisa de Lazzari;Montserrat Plana;Pedro Castro

  • Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy.

    Anna Suy;Esteban Martínez;Oriol Coll;Montserrat Lonca

  • Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial

    Mark Sulkowski;Stanislas Pol;Josep Mallolas;Hugo Fainboim

  • Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients : A randomized controlled comparison with zidovudine monotherapy

    Christine Katlama;Didier Ingrand;Clive Loveday;Nathan Clumeck

  • Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.

    Ulrich A. Walker;Jochen Bäuerle;Montse Laguno;Javier Murillas

  • Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study.

    M. Martin;E. Del Cacho;C. Codina;M. Tuset

  • Overview of SARS-CoV-2 infection in adults living with HIV.

    Juan Ambrosioni;José Luis Blanco;Juliana M Reyes-Urueña;Mary-Ann Davies

  • Sustained Virological Response to Interferon Plus Ribavirin Reduces Non-Liver-Related Mortality in Patients Coinfected With HIV and Hepatitis C Virus

    Juan Berenguer;Elena Rodríguez;Pilar Miralles;Miguel A. Von Wichmann

  • Acute hepatitis C in HIV-infected individuals : recommendations from the European AIDS Treatment Network (NEAT) consensus conference The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel

    Matthieu Albert;Jose Benito;Sanjay Bhagani;Christoph Boesecke

  • Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

    José R Arribas;Pierre-Marie Girard;Roland Landman;Judit Pich

  • Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy.

    Esteban Martínez;Miguel Angel García-Viejo;José Luis Blanco;Luis Bianchi

  • Disseminated Candidiasis in Addicts Who Use Brown Heroin: Report of 83 Cases and Review

    Josep Bisbe;Josep M. Miro;Xavier Latorre;Asuncion Moreno

  • Visceral leishmaniasis in patients infected with human immunodeficiency virus

    C. Montalban;J.L. Calleja;A. Erice;F. Laguna

  • Clinical Course and Prognostic Factors of Progressive Multifocal Leukoencephalopathy in Patients Treated With Highly Active Antiretroviral Therapy

    Juan Berenguer;Pilar Miralles;Julio Arrizabalaga;Esteban Ribera

  • Pseudomonas aeruginosa Bacteremia: Univariate and Multivariate Analyses of Factors Influencing the Prognosis in 133 Episodes

    J. Bisbe;Jose M. Gatell;Jorge Puig;Jose Mallolas

  • Incidence and causes of death in HIV‐infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area

    E Martínez;A Milinkovic;E Buira;E de Lazzari

Frequent Co-Authors

José M. Gatell
José M. Gatell University of Barcelona
José M. Miró
José M. Miró University of Barcelona
Felipe García
Felipe García University of Barcelona
Pere Domingo
Pere Domingo Autonomous University of Barcelona
Tomás Pumarola
Tomás Pumarola Vall d'Hebron Institut de Recerca
Juan Berenguer
Juan Berenguer Hospital General Universitario Gregorio Marañón
Federico Pulido
Federico Pulido Complutense University of Madrid
Hernando Knobel
Hernando Knobel Autonomous University of Barcelona
Maria Angeles Marcos
Maria Angeles Marcos University of Barcelona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens doors to diverse career paths, many of which intersect with the healthcare and information management fields. For those interested in combining patient care with holistic health practices, exploring how to become a functional medicine nurse practitioner can be a rewarding option. This role bridges clinical expertise with functional medicine principles to improve patient outcomes.

Alternatively, careers in medical coding and health information often complement a microbiology background. Becoming a certified professional coder (CPC) can provide valuable skills in medical billing and documentation. More information on this can be found by exploring the cpc certification and its career pathways.

For those drawn to the management side of healthcare data, pursuing a degree in health information management is a smart move. Entry-level professionals in this field enjoy competitive salaries and strong job prospects. Details about health information management salary entry-level can help guide your decision-making.

To strengthen your credentials, consider enrolling in an accredited online health information management degree cahiim program. These programs ensure you meet industry standards and prepare you for a successful career in healthcare information management.

Best Scientists Citing Josep Mallolas

Trending Scientists